915100-83-3

Basic information

• Product Name: [(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester
• Synonyms: [(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester
• CAS NO: 915100-83-3
• Molecular Formula: C₁₅H₁₉F₃N₂O₂
• Molecular Weight: 316.3187696
• Mol File: 915100-83-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester(915100-83-3)
• EPA Substance Registry System: [(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester(915100-83-3)

Safety Data

• Hazardous Substances Data: 915100-83-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
[(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester is used as a precursor in the pharmaceutical industry for the synthesis of various drugs. Its versatile reactivity allows it to undergo a wide range of chemical transformations, making it a valuable component in drug development.
Used in Agrochemical Synthesis:
In the agrochemical industry, [(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester is used as a starting material for the creation of different agrochemicals, contributing to its broad utility in chemical research and product development.
Used in Medicinal Chemistry Research:
[(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester is also utilized in medicinal chemistry research, where it is studied for its potential application as an antifungal and anesthetic agent. Its unique structure and properties make it a promising candidate for further investigation and development in the medical field.
Safety Considerations:
It is important to handle [(3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester with caution and adhere to proper safety protocols when working with it in laboratory settings, as it may pose health and environmental risks if not managed properly.

Upstream product

• 915100-66-2 (E)-1,2,4-trifluoro-5-(2-nitrovinyl)benzene 
• 936251-01-3 [trans-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 956924-25-7 2-nitro-1-(2,4,5-trifluorophenyl)ethanol 
• 165047-24-5 2,4,5-trifluorobenzaldehyde 
• 936251-05-7 C₁₇H₁₅F₃N₂O₂ 
• 936251-01-3 [(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 915100-75-3 tert-butyl (3R,4S)-4-(2,4,5-trifluorophenyl)-1-(6-chloropyrimidin-4-yl)pyrrolidin-3-ylcarbamate 
• 937738-02-8 C₂₅H₂₆F₃N₅O₄S 
• 915100-76-4 (3R,4S)-1-(6-thien-3-ylpyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine 
• 936251-07-9 tert-butyl (3R,4S)-1-(4-chloro-1,3,5-triazin-2-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylcarbamate 
• 1056480-13-7 tert-butyl (3R,4S)-1-(2,6-dichloropyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylcarbamate 
• 1245507-06-5 [(3R,4S)-1-(5-{(R)-3-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]butoxy}pyrimidin-2-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 

Relevant articles and documents

1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR1 19. Compounds having stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

1,4 DI SUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS

Therapeutic compounds are disclosed having the general formula (1) that are useful for the treatment of metabolic disorders, including type II diabetes.The compounds have activity as agonists of GPR1 19. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compotmds of the following formula (I) which have activity as agonists of GPR 119 and are useful for the treatment of metabolic disorders including type II diabetes.

(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization

A series of pyrrolidine based inhibitors of dipeptidyl peptidase IV were developed from a high throughput screening hit for the treatment of type 2 diabetes. Potency, selectivity, and pharmacokinetic properties were optimized resulting in the identification of a pre-clinical candidate for further profiling.

Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit

A novel series of pyrrolidine-constrained phenethylamines were developed as dipeptidyl peptidase IV (DPP4) inhibitors for the treatment of type 2 diabetes. The cyclohexene ring of lead-like screening hit 5 was replaced with a pyrrolidine to enable paralle